<DOC>
	<DOC>NCT01003886</DOC>
	<brief_summary>This study aims to assess the safety, tolerability and efficacy of Doxazosin GITS in Filipino patients diagnosed with Benign Prostatic Hyperplasia (BPH) under the usual clinical care setting.</brief_summary>
	<brief_title>A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)</brief_title>
	<detailed_description>This is an open label study. All patients prescribed with Doxazosin GITS can be enrolled in this study.</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Doxazosin</mesh_term>
	<criteria>Subjects that will be included must be consistent with the approved label indication of Doxazosin mesylate GITS in the Philippines, which includes adult male diagnosed with BPH, and who are prescribed with Doxazosin mesylate GITS. Subjects with condition that are contraindicated with Doxazosin mesylate GITS based on the approved labeling in the Philippines.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>post marketing surveillance Filipino benign prostatic hyperplasia BPH Doxazosin GITS</keyword>
</DOC>